caa a22 4500 475824687 CHVBK 20180406123828.0 cr unu---uuuuu 170329e20001001xx s 000 0 eng 10.1023/A:1018774812613 doi (NATIONALLICENCE)springer-10.1023/A:1018774812613 Effect of Coronary Thrombolysis on the Plasma Concentration of Osteonectin (SPARC, BM40) in Patients with Acute Myocardial Infarction [Elektronische Daten] [Victor Serebruany, Dan Atar, Selva Murugesan, Scott Jerome, Husam Semaan, Paul Gurbel] Osteonectin is a phosphoglycoprotein exclusively located in bone and platelet α-granules. Human platelet-derived osteonectin is released into plasma after thrombin-induced activation. Recognizing the unique distribution of the osteonectin pool, we first sought to investigate whether osteonectin could serve as a sensitive marker of platelet activity, and identify patients with acute myocardial infarction (AMI). The second objective was to define the effects of thrombolytic therapy in these patients on the plasma concentrations of osteonectin at prespecified time points following attempted reperfusion. Osteonectin levels by ELISA were determined in AMI patients before thrombolysis and at 3, 6, 12, and 24 hours thereafter and compared with 12 healthy controls. At baseline, soluble osteonectin plasma levels were similar between controls (447.7±20.6 ng/ml) and AMI patients (425.7±43.3 ng/mL; p=NS). A significant increase of the soluble osteonectin was observed at 3 hours after thrombolysis (519.4±26.9 ng/mL; p=0.03), and was followed by a decrease to baseline levels at 6 hours after attempted reperfusion. Contrary to expectations, the plasma osteonectin level in our pilot study was not a sensitive marker distinguishing patients with AMI. The early peak of soluble osteonectin at 3 hours after thrombolytic therapy is most likely not related to coronary thrombolysis per se but rather to the phasic changes of platelet activity during myocardial ischemia-reperfusion. The unquestionable platelet origin of this protein and the lack of elevated plasma levels of this α-granule constituent, challenge the postulate of uniform platelet activation in AMI patients. Kluwer Academic Publishers, 2000 osteonectin nationallicence acute myocardial infarction nationallicence thrombolysis nationallicence human nationallicence Serebruany Victor Sinai Center for Thrombosis Research, Baltimore, Maryland, USA aut Atar Dan State University Hospital (Rigshuspitalet), Copenhagen, Denmark aut Murugesan Selva Sinai Center for Thrombosis Research, Baltimore, Maryland, USA aut Jerome Scott Sinai Center for Thrombosis Research, Baltimore, Maryland, USA aut Semaan Husam Sinai Center for Thrombosis Research, Baltimore, Maryland, USA aut Gurbel Paul Sinai Center for Thrombosis Research, Baltimore, Maryland, USA aut Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 10/2(2000-10-01), 197-202 0929-5305 10:2<197 2000 10 11239 https://doi.org/10.1023/A:1018774812613 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1018774812613 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Serebruany Victor Sinai Center for Thrombosis Research, Baltimore, Maryland, USA aut NATIONALLICENCE 700 1- Atar Dan State University Hospital (Rigshuspitalet), Copenhagen, Denmark aut NATIONALLICENCE 700 1- Murugesan Selva Sinai Center for Thrombosis Research, Baltimore, Maryland, USA aut NATIONALLICENCE 700 1- Jerome Scott Sinai Center for Thrombosis Research, Baltimore, Maryland, USA aut NATIONALLICENCE 700 1- Semaan Husam Sinai Center for Thrombosis Research, Baltimore, Maryland, USA aut NATIONALLICENCE 700 1- Gurbel Paul Sinai Center for Thrombosis Research, Baltimore, Maryland, USA aut NATIONALLICENCE 773 0- Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 10/2(2000-10-01), 197-202 0929-5305 10:2<197 2000 10 11239 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer